Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
← catalyst calendarNCT06992609 · readout in 1,046 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
68actual
Sites
14
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-15 | actual | When the study began enrolling |
| Primary completion | 2029-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Carcinoma
Intervention
- Drug: Durvalumab — also filed as Consolidation treatment
Primary outcome
what the primary-completion date above is the date OFTo describe the safety profile of durvalumab for patients with LS-SCLC who have not progressed following CRT.
measured 90 days after last dose of durvalumab of the last patient.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed